Verrica Pharmaceuticals Inc (VRCA)
1.00
+0.01
(+1.01%)
USD |
NASDAQ |
Nov 22, 16:00
1.00
0.00 (0.00%)
After-Hours: 20:00
Verrica Pharmaceuticals Debt to Equity Ratio: -1.272 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | -1.272 |
| June 30, 2024 | -3.214 |
| March 31, 2024 | 28.41 |
| December 31, 2023 | 2.169 |
| September 30, 2023 | 1.002 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.00 |
| June 30, 2022 | 2.589 |
| March 31, 2022 | 1.652 |
| December 31, 2021 | 1.279 |
| September 30, 2021 | 1.012 |
| June 30, 2021 | 0.7862 |
| March 31, 2021 | 0.658 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-3.214
Minimum
Jun 2024
28.41
Maximum
Mar 2024
2.338
Average
0.7862
Median
Jun 2021
Debt to Equity Ratio Benchmarks
| Biomarin Pharmaceutical Inc | 0.1098 |
| Elite Pharmaceuticals Inc | 0.1575 |
| Eagle Pharmaceuticals Inc | -- |
| TELA Bio Inc | -6.532 |
| Terns Pharmaceuticals Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 32.93M |
| Total Liabilities (Quarterly) | 66.98M |
| Shareholders Equity (Quarterly) | -34.05M |
| Current Ratio | 1.341 |
| Net Debt Paydown Yield | -13.10% |